|
Prostate carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
Both PSA and DNA ploidy analysis by flow cytometry appear to be valuable indicators in the evaluation of patients with prostatic carcinoma.
|
1710533 |
1991 |
|
Prostate carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
Prostate-specific antigen (PSA) has emerged as the most useful marker for management of patients with prostate cancer.
|
1379363 |
1992 |
|
Prostate carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
Quantitative estimation of tissue prostate specific antigen, deoxyribonucleic acid ploidy and cytological grade in fine needle aspiration biopsies for prognosis of hormonally treated prostatic carcinoma.
|
1380992 |
1992 |
|
Prostate carcinoma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
We analyzed data from a cohort of 161 patients to determine whether there were any racial differences in PSA levels prior to treatment in local-regional prostate cancer.
|
1284591 |
1993 |
|
Prostate carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
Forty-three patients with untreated prostate cancer had serial PSA measurements over an average time span of 30 months.
|
7685704 |
1993 |
|
Prostate carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
Prostate-specific antigen (PSA), a M(r) 34,000 serine protease, is recognized as a useful marker for the detection and prognosis of patients with prostate cancer.
|
7684949 |
1993 |
|
Prostate carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
Relationship of tumor DNA-ploidy to serum prostate-specific antigen doubling time after radiotherapy for prostate cancer.
|
7526527 |
1994 |
|
Prostate carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
Newer applications of serum prostate-specific antigen in the management of prostate cancer.
|
7524153 |
1994 |
|
Prostate carcinoma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
The serum prostate specific antigen (PSA) level was determined in 311 men with documented prostate cancer (stages T1cN0, T2N0 and T3N0) before bilateral pelvic lymphadenectomy and radical retropubic prostatectomy.
|
7514689 |
1994 |
|
Prostate carcinoma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
Blood from men with hormone-refractory and progressive CaP demonstrated a higher frequency of PSA mRNA detectable by RT-PCR (10 of 20 patients).
|
7527455 |
1994 |
|
Prostate carcinoma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
The present study was designed to elucidate the role of 13-cis-retinoic acid (RA) in regulation of PSA and the tumorigenic potential of the human prostate cancer cell line LNCaP.
|
7523313 |
1994 |
|
Prostate carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
The authors used polymerase chain reaction (PCR) amplification of the prostate-specific antigen (PSA) mRNA sequence reverse-transcriptase PCR (RTPCR) and immunohistochemistry using a PSA antibody to identify metastatic prostate cancer cells in the bone marrow of patients with prostate cancer.
|
7522952 |
1994 |
|
Prostate carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
In this model, subcutaneous co-injection of 2 non-tumorigenic human cell lines--LNCaP, a prostate cancer cell line, and MS, a bone stromal cell-line--into intact adult male mice resulted in formation of carcinomas that secreted prostate-specific antigen (PSA), a clinically useful human serum prostate cancer marker.
|
8169003 |
1994 |
|
Prostate carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
The predictive value of nuclear DNA ploidy and AT on clinical and prostate-specific antigen (PSA) progression and on overall and cause-specific survival after radical retropubic prostatectomy was assessed in 894 patients with pT3 prostate cancer.
|
7544934 |
1995 |
|
Prostate carcinoma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
The use of a highly specific promoter-driven gene vector will allow selective expression of therapeutic genes within PSA-producing prostate cancer cells, providing a unique strategy for prostate cancer gene therapy.
|
8573614 |
1995 |
|
Prostate carcinoma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
We have studied the expression of prostate-specific antigen (PSA) mRNA by reverse transcriptase-polymerase chain reaction in peripheral blood of 25 patients with cancer of the prostate (CAP), four with benign prostatic hyperplasia (BPH), two with renal stones, three with other types of cancer, and six healthy male and three female controls.
|
7533062 |
1995 |
|
Prostate carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
Indeed, a new era of PSA testing has been entered, and the entire field of prostate cancer will benefit.
|
7538236 |
1995 |
|
Prostate carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
Human prostate-specific antigen (PSA) has been shown as an aid in the early detection of prostate cancer (W. J. Catalona et al., J.Am.Med.
|
7538903 |
1995 |
|
Prostate carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
Currently, the TNM (Tumor, Lymph Node, Metastasis) staging system, histologic grading (Gleason system), and serum prostate-specific antigen are recommended for general use as prognostic markers in prostate cancer.
|
7503660 |
1995 |
|
Prostate carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
A molecular assay that detects prostate specific antigen (PSA)-synthesizing cells in the peripheral circulation of patients with prostate cancer is described.
|
8826922 |
1995 |
|
Prostate carcinoma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
We examined the antitumor effect of suramin in an in vivo mouse model of hormone-refractory human prostate cancer to determine whether a decrease in PSA levels reflects a reduction in tumor growth (volume).
|
8637045 |
1996 |
|
Prostate carcinoma
|
0.200 |
PosttranslationalModification
|
disease |
BEFREE |
Prostate-specific antigen promoter driven gene therapy targeting DNA polymerase-alpha and topoisomerase II alpha in prostate cancer.
|
8712704 |
1996 |
|
Prostate carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
This makes PSA an attractive candidate for use as a target antigen in the immunotherapy of prostate cancer.
|
8830740 |
1996 |
|
Prostate carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
We evaluated whether knowledge of preoperative free prostate-specific antigen (f-PSA), complexed (c-PSA), and total (t-PSA) concentrations or the ratios thereof (f-PSA/t-PSA, c-PSA/t-PSA, and f-PSA/c-PSA) could improve upon the staging of prostate cancer when compared with standard PSA testing (t-PSA).
|
8753736 |
1996 |
|
Prostate carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
With NSE, BCL2 and PSA (prostate-specific antigen) as identifying markers, the model specifies a putative progression sequence of the prostate cancer cell types.
|
8543402 |
1996 |